“We are on the cusp of a revolution in the treatment of depression,” said Anthony Rothschild, MD, the Irving S. and Betty Brudnick Chair in Psychiatry and professor of psychiatry, in a new Voices of UMassMed podcast.
Dr. Rothschild is a physician-scientist who has spent his career trying to uncover better treatment options for people battling depression, including the new drug related to ketamine that is on track to receive FDA approval in 2019. In the interview, he discussed the potential benefits and side effects of Esketamine for people who have not responded to other available treatments.
Listen to the full podcast at https://www.umassmed.edu/news/voices. Subscribe to the podcast on SoundCloud and iTunes by searching for Voices of UMassMed. To share feedback and ideas for future episodes, e-mail the Office of Communications at UMassChanCommunications@umassmed.edu.
